Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Estrogen Receptor and/or Progesterone Receptor Positive 1Ependymoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

relacorilant 2pembrolizumab 2cabozantinib 2tariquidar 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Gefitinib 1Floxuridine 1Dexamethasone 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adrenal Cortex Neoplasms × Pharmacogenomic Variants × Clear all
NCT03370718 2024-12-10

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled 5 charts

Adrenal Cortex Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡